Progesterone-Linked Immune Changes to Help Pregnancies with Preeclampsia
Official title: Project IV
Funded at University of Mississippi Med Ctr · NIH-11397765 · Data updated 2026-11-12
A safety-focused study will test whether giving a progesterone-derived treatment (17-OHPC) can favorably change the immune and inflammatory signals in pregnant people with preeclampsia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Mississippi Med Ctr NIH-funded |
| Lab location | 1 site (Jackson, United States) |
| Project start | August 15, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $183,564 |
| NIH project number | 5U54HL170290-02 |
| Project ID | NIH-11397765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant people diagnosed with preeclampsia who are considered candidates for 17-OHPC intervention.
✕Less likely to help
Pregnant individuals without preeclampsia or those not eligible for 17-OHPC may not benefit.
What this research studies
Preeclampsia is a dangerous pregnancy complication where inflammation and immune balance shift. This project explores whether supplementing with 17-OHPC can boost protective factors like PIBF and reduce harmful inflammation and blood pressure in affected pregnancies. The study builds on early data showing improved PIBF and clinical signs when 17-OHPC is added, aiming to understand how these changes relate to maternal and fetal health. If successful, the approach could extend pregnancy duration and reduce complications for mothers and babies.
Why it matters
Potential benefit: If successful, this approach could lower inflammation and blood pressure, potentially prolonging pregnancy and reducing risks for mother and baby.
How similar studies have gone: Preliminary data suggest improvements in PIBF and inflammatory markers with 17-OHPC, but larger studies are needed to confirm benefits.
Where this research is happening
-
University of Mississippi Med Ctr
Jackson, United States Active
Researchers
- Principal investigator: Amaral, Lorena M — University of Mississippi Med Ctr
- Study coordinator: Amaral, Lorena M
Related research
Other NIH-funded projects on the same topics.
-
Understanding how HTLV-1 hides inside immune cells to drive ATLL
A research project at the University of Mississippi Medical Center is studying how HTLV-1 makes monocytes and macrophages harbor the virus, with the goal of finding ways to restore the body’s own ability to clear it and slow ATL/ATLL progression.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Fentanyl use during pregnancy and its effects on mom, placenta, and baby
This project studies how fentanyl use during pregnancy affects a mother's health, the placenta, and the development of the child.
-
Professional Development Core for Clinical & Translational Research in Mississippi
A grant to strengthen clinical and translational research training and community-engaged programs in Mississippi to accelerate care for chronic diseases including diabetes and dementia.
-
RS Core: Support for Clinical Research Development and Population Health in Mississippi
A patient-facing program to help doctors and researchers design and run clinical, translational, and community health studies more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.